says were purchased from Amersham Pharmacia Biotech (Buckinghamshire, England, U.K.).
Cell Culture and Samples Detection The MA-10 cell line was generously provided by Dr. Ing-Cherng Guo (National Taiwan University, Taipei, Taiwan R.O.C.) and Dr. Bon-Chu Chung (Academia Sinica, Taipei, Taiwan R.O.C.) and has been maintained since an earlier study. 21 ) 5ϫ10 5 cells/ml medium or 5ϫ10 4 cells/100 ml medium were plated in 24-well plates or 96-well plates, respectively. Cells were grown for 24 h in Weymouth medium containing 15% horse serum. Then, the medium was aspirated and the cells were washed with phosphate buffer saline (PBS). Chemicals and/or KCZ were continuously added to the serum-free Weymouth medium at various concentrations and times. Cells were maintained in a humidified incubator containing 5% CO 2 at 37°C. After incubation, media were collected and progesterone concentrations and cAMP levels in each treatment were determined by chemiluminescent detection and cAMP EIA, respectively. Progesterone samples were measured by the detector, VITROS Eci, Ortho-Clinical Diagnostics Inc., a Johnson & Johnson company (Rochester, NY, U.S.A.).
Statistics All experiments, with duplicates of each treatment, were repeated at least three times. Data of all experiments were analyzed by analysis of variance (ANOVA), and then the least significant difference (LSD) was used to determine the difference between treatments.
RESULTS

Dose and Time Course Effects of KCZ on Progesterone
Production in MA-10 Cells The effect of different incubation times (1, 2, 3 h) with different concentrations of KCZ (2, 20 mM) on progesterone production in MA-10 cells is shown in Fig. 1 . The progesterone levels after 20 mM KCZ treatment were lower than those after 2 mM KCZ treatment. When incubated with 20 mM KCZ, the production of progesterone decreased at least 6-fold compared with the basal level. Meanwhile, significant difference in progesterone production was suppressed by KCZ compared with the basal level from 1 to 3 h incubation, especially those values since 2 h after KCZ treatment.
Effect of KCZ on Progesterone Production in MA-10 Cells after LH Stimulation The effect of different LH dosages (5, 25 mg/ml) on progesterone secretion in MA-10 cells without and with KCZ incubation (2, 20 mM) is shown in Fig. 2 . Pretreatment (2 h) with 2 and 20 mM KCZ led to an inhibition of basal progesterone secretion and also of progesterone secretion after stimulation with different LH dosages (5, 25 mg/ml; Fig. 2 3) . IBMX also increased the progesterone production, but the values were less than those of LH stimulation. Moreover, the elevated progesterone levels by IBMX treatment were not significantly inhibited by 20 mM KCZ (Fig. 3) . Besides the preliminary tests, basal and LH (5 mg/ml) stimulated progesterone decreased with KCZ (20 mM) treatment, addition of db-cAMP (10 mM) led to further significant increase of basal and LH-stimulated progesterone secretion in the presence of 20 mM KCZ ( Table 1) . Stimulation of the catalytic subunit of the adenylate cyclase system with 5 mM forskolin led to significant progesterone and cAMP production, which was also significantly inhibited by 20 mM KCZ (Table 2 ). Sodium fluoride (1 mM) incubation which stimulated the G S protein significantly increased progesterone production which was significantly suppressed by 20 mM KCZ. Meanwhile, cAMP releases after 1 mM sodium fluoride treatment were significantly increased and significantly suppressed by 20 mM KCZ (Table 2 ).
DISCUSSION
Our data demonstrated that KCZ inhibits secretion of progesterone in a dose dependent fashion from 1 to 3 h in MA-10 mouse Leydig tumor cells (Fig. 1) . Similar dose-dependent inhibition of progesterone synthesis by KCZ was shown in a previous study, 22) KCZ inhibited the hCG-and db-cAMP-stimulated progesterone production from MA-10 Leydig cells by directly inhibiting the activity of cholesterol side-chain cleavage enzyme. 22) Inhibition of C [17] [18] [19] [20] lyase by KCZ has been demonstrated by an increase in the ratio of precursor (17a-hydroxyprogesterone or 17a,20a-dihydroxyprogesterone or progesterone or all) to product (androstenedione or testosterone) both in vivo 13, 16) and in vitro. [23] [24] [25] Moreover, cholesterol side-chain-cleavage blockade by KCZ has been demonstrated in both testicular and adrenal tissue preparations. 26, 27) Therefore, the significantly inhibited progesterone production in MA-10 cells by KCZ corresponds to the results of in vitro studies in rat testicular microsomes with KCZ. It has shown that cholesterol side-chain-cleavage has a higher sensitivity to KCZ than does C 17-20 lyase. 27) MA-10 cells released progesterone into the medium in response to different doses of LH (Fig. 2) ; this release was coupled with an increase of cAMP levels (Fig. 3) . 28) That cAMP is the second messenger to LH stimulation of progesterone in MA-10 Leydig tumor cells was demonstrated by the observation that added db-cAMP also led to a rise in progesterone production. Moreover, inhibition of phosphodiesterase with IBMX 29) led to an increase in cAMP production and progesterone secretion.
The stimulation of the catalytic component of the adenylate cyclase holoenzyme with forskolin 30) also induced a significant increase in cAMP and progesterone production in MA-10 cells. A stimulatory agent of the G S protein of adenylate cyclase system, like sodium fluoride, 30) also led to an increase in progesterone and cAMP production in MA-10 cells. KCZ suppressed basal cAMP and progesterone production from these cells (Figs. 1-3 ). Basal phosphodiesterase activity was inhibited by IBMX 29) indicating that adenylate cyclase is required to maintain progesterone biosynthesis which is inhibited by KCZ (Fig. 3) . Therefore, KCZ inhibited progesterone secretion and cAMP production after inhibiting of phosphodiesterase by IBMX and stimulating by different doses of LH (Figs. 2, 3) . MA-10 cells have LH/hCG receptors and respond to LH/hCG and cAMP via increased production of progesterone. 21, 22) KCZ decreased cAMP production by blockading the pathway of catalytic component of the adenylate cyclase in the present study, and was also an inhibitor of the cholesterol side-chain-cleavage enzyme. [1] [2] [3] [4] [5] [6] [7] [8] [9] 11) Therefore, the significant inhibitory effect of KCZ incubation on LH-stimulated progesterone production in MA-10 cells was not noted in combined IBMX treatment (Fig. 3) . However, the reason a lower extent of increased progesterone values did not match the higher cAMP levels after IBMX treatment needs further investigation. In contrast, the hCG-stimulated cAMP production was not inhibited by KCZ. 22) Chaudhary and Stocco suggested that the locus of hCG-stimulated progesterone synthesis was not related to cAMP production in MA-10 cells. 22) This meant that the inhibitory effects of KCZ between progesterone and cAMP production after LH stimulation (Figs. 2, 3 ) interacted in MA-10 cells. Addition of exogenous db-cAMP to MA-10 cells pretreated with KCZ neutralized the inhibitory effect of KCZ on progesterone production in the basal state and after LH stimulation ( Table 1) . Stimulation of the G S protein of the adenylate cyclase system by sodium fluoride was suppressed by KCZ in the same fashion as the forskolin stimulated adenylate cyclase activity (Table 2) .
In summary, our data suggested that KCZ inhibits cAMP generation and progesterone biosynthesis at the direction of the catalytic component of the adenylate cyclase holoenzyme in MA-10 mouse Leydig tumor cells. MA-10 cells were incubated 24 h. Different compounds were added to selected wells and aliquots of the medium were removed from well at 2 h. Progesterone in the medium was measured by enhanced chemiluminescent detection. cAMP in the medium was measured by EIA. Each data in the table represents meanϮS.E. of progesterone and cAMP production of repeated experiments with triplicates in each treatment. Asterisk ( * ) indicates statistically significant difference (pϽ0.05) as compared with control (without KCZ pretreatment) levels. Different letters beside the values indicates statistically significant difference (pϽ0.05) among treatments.
